Urolithin A is a gut microbiome-derived metabolite generated from dietary ellagitannins and ellagic acid found in pomegranate, walnuts, and some berries.[1][2] Interest in urolithin A has grown because it is one of the few oral small molecules with reproducible human target-engagement signals for mitochondrial quality control, particularly mitophagy.[3][4]
For neurodegenerative disorders, the clinical thesis is mechanistically coherent but still translationally early: urolithin A may reduce accumulation of dysfunctional mitochondria, blunt inflammasome signaling, and improve cellular stress resilience in vulnerable neurons and glia.[5][6][7] The strongest human efficacy signals to date come from muscle and systemic mitochondrial endpoints rather than definitive disease-modifying outcomes in Alzheimer's disease, Parkinson's disease, corticobasal syndrome (CBS), or progressive supranuclear palsy (PSP).[3:1][4:1]
This monograph focuses on evidence quality, mechanistic plausibility for CBS/PSP, practical dosing and safety considerations, and a realistic implementation framework while clinical uncertainty remains substantial.
Production of urolithin A is microbiome-dependent and highly inter-individual. Many adults are low producers without supplementation, and "metabotype" variation likely contributes to variable clinical response.[1:1][8][9] This matters for neurology because endogenous production alone may be insufficient in older patients with dysbiosis, frailty, constipation, antimicrobial exposure, or restrictive diets.
Key implications:
Urolithin A appears to activate mitochondrial quality control through integrated effects on autophagy initiation, mitochondrial dynamics, inflammatory signaling, and proteostatic stress pathways.[3:2][5:1][7:1]
Mitochondrial injury, lysosomal stress, and maladaptive neuroinflammation are shared features across tauopathies and synucleinopathies.[6:1][10][11] In experimental systems, mitophagy enhancement can reduce amyloid/tau burden and improve behavioral outcomes, supporting biological plausibility for intervention upstream of irreversible cell loss.[5:2]
For CBS/PSP specifically, the rationale is indirect but compelling:
The foundational 2016 preclinical study demonstrated that urolithin A induces mitophagy and improves muscle function/lifespan-related phenotypes across species.[12] While not a neurodegeneration trial, it established pharmacologic plausibility and a reproducible biological signature.
Mitophagy-focused AD model work shows that restoring mitophagy can reduce amyloid and tau pathology and improve cognition, supporting the target class rationale.[5:3] Subsequent urolithin A-focused studies report improvements in mitochondrial stress signaling, inflammatory tone, and cognitive readouts in AD-like models, though effect sizes vary by model and dosing window.[7:2][13][14]
Interpretation:
In toxin and inflammatory PD models, urolithin A has been linked to improved dopaminergic neuron resilience, reduced NLRP3-linked inflammatory signaling, and better motor/cognitive phenotypes.[6:2][15]
Confidence limits:
Amyotrophic lateral sclerosis (ALS) involves progressive motor neuron degeneration with significant mitochondrial dysfunction. Urolithin A has shown promise in preclinical ALS models, with studies reporting:
However, human clinical trials specifically in ALS populations remain limited, and translation to clinical benefit requires further validation.
FTD and Huntington's disease (HD) both involve mitochondrial dysfunction and protein aggregation. While direct urolithin A studies in FTD and HD are sparse, biological plausibility exists:
Clinical evidence in these populations is currently theoretical, and trials would be needed to establish efficacy.
Several brain injury models suggest urolithin A may preserve blood-brain barrier integrity, reduce apoptosis, and improve neurological outcomes, potentially via AMPK/mTOR-autophagy axis effects.[17][18][19] These are not direct neurodegenerative disease trials, but they support a broader CNS stress-protection profile.
Human evidence is strongest for mitochondrial and functional endpoints in aging adults rather than diagnosed neurodegenerative disease modification.
The first randomized human trial program found urolithin A safe and associated with molecular signatures consistent with improved mitochondrial and cellular health.[3:3] Subsequent placebo-controlled work in older adults demonstrated improvements in muscle endurance and mitochondrial-related biomarkers.[4:2]
A randomized controlled trial in middle-aged adults reported improved muscle strength, exercise performance, and mitochondrial biomarkers, representing the most robust efficacy signal in humans so far.[20] In this task context, the "ATLAS" label should be interpreted as a muscle/healthy-aging efficacy program, not as definitive proof of disease modification in CBS/PSP or AD.
Recent placebo-controlled data suggest possible improvement in age-related immune decline phenotypes, which may be relevant to inflammaging-mediated neurodegeneration, but this remains hypothesis-generating for neurology.[21]
Reasonable claims:
Not yet justified:
CBS and PSP involve high energetic strain, network-level disconnection, gait/falls burden, dysphagia progression, and limited disease-modifying options. A mitochondrial quality-control intervention is attractive because it can be layered with rehabilitation and symptomatic care without requiring disease-specific mutation targeting.
Potentially relevant domains:
Most human trial data cluster around 500 mg to 1000 mg daily oral dosing.[3:4][4:3][20:1]
Suggested pragmatic protocol for specialist supervision:
Because expected effects are gradual, reassess at 8-12 weeks with pre-specified functional goals rather than day-to-day symptom fluctuation.
Potential tracking metrics:
Across controlled human studies, urolithin A has shown favorable tolerability, with mostly mild adverse effects and no consistent signal for severe toxicity at trial doses.[3:5][4:4][20:2]
Commonly reported mild effects:
Use extra caution in:
Definitive interaction maps are incomplete. In clinical practice:
Urolithin A is best conceptualized as a "mitochondrial support layer" rather than monotherapy.
Potential rational pairings:
Design principle: add one intervention at a time and preserve interpretability of response.
Rapamycin and related mTOR inhibitors provide robust autophagy activation but can introduce immunometabolic tradeoffs, mouth ulcers, edema, and drug-interaction complexity in fragile older adults. Urolithin A generally provides a narrower and milder "mitochondrial housekeeping" signal with a better tolerability profile in current datasets.[3:6][4:5][20:3]
Clinical implication for CBS/PSP programs:
NAD+ precursor approaches and urolithin A are mechanistically complementary rather than exclusive. NAD+ strategies emphasize redox and sirtuin signaling; urolithin A emphasizes mitophagy and damaged-organelle clearance.[7:3][10:1][22]
In practical sequencing, many clinicians trial one pathway first, then layer the second only after objective response tracking to avoid confounded interpretation.
Polyphenol blends may confer antioxidant and anti-inflammatory support, but they are often compositionally heterogeneous and less target-explicit. Urolithin A offers a more defined metabolite with human trial datasets that include mechanistic biomarker readouts.[3:7][4:6][20:4]
For a CBS/PSP supportive-care stack, urolithin A currently sits in the "biologically credible, clinically early" category:
Because direct evidence is limited, trial quality will determine whether urolithin A remains a plausible adjunct or becomes a validated disease-modifying option.
Primary endpoint candidates:
Secondary endpoint candidates:
Exploratory biomarker panel:
Most failures in neuroprotection come from underpowered, short-duration trials with weak endpoint selection. A rigorously designed CBS/PSP trial can resolve whether urolithin A's biomarker/muscle benefits translate into neurologic benefit or remain peripheral effects.
The following approach can reduce bias and avoid endless low-value supplementation:
This framework respects uncertainty while still allowing rational experimentation in high-need disorders with limited options.
Mitophagy biology is compelling, yet confirmed disease-modifying outcomes in CBS/PSP are not established. This mismatch is common in neurodegeneration and should be communicated transparently.
Human trials show systemic functional gains, but the exposure required for central effects in tauopathy populations is unknown. Peripheral improvement does not automatically imply CNS disease modification.
Urolithin A likely performs best where viable neuronal networks remain. In advanced disease with major structural loss, mitochondrial support may be insufficient to produce visible functional gains.
Priority experiments:
Decision-making threshold proposal:
| Dimension | Score | Rationale |
|---|---|---|
| Mechanistic Clarity | 8 | Strong convergence on mitophagy/mitochondrial signaling targets with cross-model reproducibility. |
| Clinical Evidence | 4 | Human RCTs are encouraging but mostly outside diagnosed neurodegenerative cohorts. |
| Preclinical Evidence | 7 | Multiple AD/PD/injury models show favorable directionality. |
| Replication | 6 | Repeated signal across studies, but heterogeneous methods/formulations. |
| Effect Size | 5 | Moderate effects in non-neurologic functional endpoints; uncertain CNS clinical magnitude. |
| Safety/Tolerability | 8 | Generally favorable across controlled human studies at common doses. |
| Biological Plausibility | 8 | High plausibility for mitochondrial-stress-mediated tauopathy/synucleinopathy. |
| Actionability | 7 | Orally available, implementable in specialist supportive-care programs. |
Total: 53/80
Cerdá B, Tomás-Barberán FA, Espín JC. Metabolism of antioxidant and chemopreventive ellagitannins from strawberries, raspberries, walnuts, and oak-aged wine in humans: identification of biomarkers and individual variability. J Agric Food Chem. 2005. ↩︎ ↩︎
Selma MV, Beltrán D, García-Villalba R, Espín JC, Tomás-Barberán FA. Description of urolithin production capacity from ellagic acid of two human intestinal Gordonibacter species. Food Funct. 2014. ↩︎
Andreux PA, Blanco-Bose W, Ryu D, et al. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nat Metab. 2019. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Liu Y, Andreux PA, Sica V, et al. Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial. JAMA Netw Open. 2022. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Fang EF, Hou Y, Palikaras K, et al. Mitophagy inhibits amyloid-beta and tau pathology and reverses cognitive deficits in models of Alzheimer's disease. Nat Neurosci. 2019. ↩︎ ↩︎ ↩︎ ↩︎
Zhang P, Liu X, Zhao F, et al. Urolithin A promotes mitophagy and suppresses NLRP3 inflammasome activation in lipopolysaccharide-induced BV2 microglial cells and MPTP-induced Parkinson's disease model. J Neuroinflammation. 2022. ↩︎ ↩︎ ↩︎
D'Amico D, Andreux PA, Valdés P, et al. Impact of the Natural Compound Urolithin A on Health, Disease, and Aging. Trends Mol Med. 2021. ↩︎ ↩︎ ↩︎ ↩︎
García-Villalba R, Giménez-Bastida JA, García-Conesa MT, et al. Alternative method for gas chromatography-mass spectrometry analysis of urolithins and their phase II metabolites, including glucuronides and sulfates, in biological samples. J Chromatogr A. 2012. ↩︎
Cortés-Martín A, Selma MV, Tomás-Barberán FA, et al. Where to look into the puzzle of polyphenols and health? The postbiotics and gut microbiota associated with human metabotypes. Food Funct. 2020. ↩︎
Pickrell AM, Youle RJ. The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease. Neuron. 2015. ↩︎ ↩︎
Wang X, Becker K, Levine N, et al. Pathogenic alpha-synuclein aggregates preferentially bind to mitochondria and affect cellular respiration. Acta Neuropathol Commun. 2019. ↩︎
Ryu D, Mouchiroud L, Andreux PA, et al. Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents. Nat Med. 2016. ↩︎
Sun W, Zhou S, Chang SS, et al. Urolithin A improves Alzheimer's disease cognition and restores mitophagy and lysosomal functions. Alzheimers Dement. 2024. ↩︎
Xu Y, Xu Y, Wang Y, et al. Urolithin A exhibits a neuroprotective effect against Alzheimer's disease by inhibiting DYRK1A activity. Phytomedicine. 2023. ↩︎
Wang R, Zhang Y, Li J, et al. Urolithin A protects dopaminergic neurons in experimental models of Parkinson's disease by promoting mitochondrial biogenesis through the SIRT1/PGC-1alpha signaling pathway. Food Funct. 2022. ↩︎
Preclinical evidence in ALS models is emerging, with urolithin A demonstrating mitochondrial and neuroprotective effects in SOD1 and other genetic models. See. D'Amico et al., Trends Mol Med 2021. 2021. ↩︎
Chen Y, Fu Y, Li J, et al. Urolithin A alleviates blood-brain barrier disruption and attenuates neuronal apoptosis following traumatic brain injury in mice. Neurochem Int. 2022. ↩︎
Zhang Q, Wu S, Zhu H, et al. Urolithin A alleviates early brain injury after subarachnoid hemorrhage by regulating the AMPK/mTOR pathway-mediated autophagy. Neurochem Res. 2023. ↩︎
Wang Y, Tang C, Bai Y, et al. Neuroprotective effects of urolithin A in a mouse model of intracerebral hemorrhage. Neurochem Int. 2025. ↩︎
Singh A, D'Amico D, Andreux PA, et al. Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults. Cell Rep Med. 2022. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Ah You N, Mercier S, Chabane YN, et al. Effect of the mitophagy inducer urolithin A on age-related immune decline: a randomized, placebo-controlled trial. Nat Aging. 2025. ↩︎
Reyes-Fernández A, González-Sarrías A, García-Villalba R, et al. Urolithins, gut microbiota, and health: a review of evidence and translational opportunities. Nutrients. 2022. ↩︎